INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 137 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2019. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $10,991,674 | +23.8% | 160,487 | +25.1% | 0.02% | +23.1% |
| Q1 2024 | $8,879,507 | +6.1% | 128,311 | +9.8% | 0.01% | 0.0% |
| Q4 2023 | $8,366,940 | +16.5% | 116,823 | -15.2% | 0.01% | 0.0% |
| Q3 2023 | $7,180,283 | -24.4% | 137,841 | -8.1% | 0.01% | -23.5% |
| Q2 2023 | $9,500,638 | +14.5% | 150,042 | -2.1% | 0.02% | +13.3% |
| Q1 2023 | $8,298,882 | +13.7% | 153,258 | +11.1% | 0.02% | -6.2% |
| Q4 2022 | $7,297,851 | +5.9% | 137,903 | -6.9% | 0.02% | +6.7% |
| Q3 2022 | $6,889,000 | -23.7% | 148,046 | -6.4% | 0.02% | -25.0% |
| Q2 2022 | $9,033,000 | -22.0% | 158,247 | -16.2% | 0.02% | -13.0% |
| Q1 2022 | $11,576,000 | +33.3% | 188,920 | +14.0% | 0.02% | +43.8% |
| Q4 2021 | $8,683,000 | +54.1% | 165,649 | +9.5% | 0.02% | +33.3% |
| Q3 2021 | $5,636,000 | +199.0% | 151,324 | +227.5% | 0.01% | +200.0% |
| Q2 2021 | $1,885,000 | +217.9% | 46,209 | +164.5% | 0.00% | +300.0% |
| Q1 2021 | $593,000 | +37.3% | 17,471 | +28.5% | 0.00% | 0.0% |
| Q4 2020 | $432,000 | -36.6% | 13,598 | -48.8% | 0.00% | -50.0% |
| Q3 2020 | $681,000 | +134.0% | 26,533 | +134.3% | 0.00% | +100.0% |
| Q2 2020 | $291,000 | +66.3% | 11,322 | -0.6% | 0.00% | 0.0% |
| Q1 2020 | $175,000 | +503.4% | 11,385 | +375.2% | 0.00% | – |
| Q1 2019 | $29,000 | -44.2% | 2,396 | 0.0% | 0.00% | – |
| Q4 2018 | $52,000 | 0.0% | 2,396 | 0.0% | 0.00% | – |
| Q3 2018 | $52,000 | +23.8% | 2,396 | 0.0% | 0.00% | – |
| Q2 2018 | $42,000 | -97.5% | 2,396 | -97.9% | 0.00% | -100.0% |
| Q4 2016 | $1,690,000 | -2.3% | 112,000 | -1.4% | 0.01% | -11.1% |
| Q3 2016 | $1,730,000 | -60.1% | 113,548 | +1.7% | 0.01% | -65.4% |
| Q2 2016 | $4,333,000 | +54.6% | 111,612 | +10.7% | 0.03% | +52.9% |
| Q1 2016 | $2,803,000 | -38.2% | 100,814 | +19.5% | 0.02% | -39.3% |
| Q4 2015 | $4,539,000 | – | 84,389 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 360,000 | $11,502,000 | 2.65% |
| Redmile Group, LLC | 610,171 | $19,495,000 | 1.60% |
| Pier Capital, LLC | 257,256 | $8,219,000 | 1.18% |
| WALL STREET ASSOCIATES | 358,857 | $11,465,000 | 1.08% |
| SENZAR ASSET MANAGEMENT, LLC | 161,300 | $5,154,000 | 0.88% |
| Rhenman & Partners Asset Management AB | 206,000 | $6,582,000 | 0.79% |
| EAM Investors, LLC | 152,389 | $4,869,000 | 0.57% |
| EDMOND DE ROTHSCHILD (SUISSE) S.A. | 50,000 | $1,598,000 | 0.51% |
| Visium Asset Management, LP | 1,051,479 | $33,595,000 | 0.48% |
| SPHERA FUNDS MANAGEMENT LTD. | 128,000 | $4,090,000 | 0.40% |